A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Hemay022+AIDrug: Lapatinib+Capecitabine
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 339
- Registration Number
- NCT06313983
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT05407246
- Locations
- 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, Hubei, China
🇨🇳Chenzhou first people's Hospital, Chenzhou, Hunan, China
🇨🇳The First Affiliated Hospital of Bengbu Medical University, Hefei, Anhui, China
A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Hemay007 800 mg QD groupDrug: Hemay007 1200 mg QD groupDrug: Hemay007 600 mg QD groupDrug: Hemay007 placebo group
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 140
- Registration Number
- NCT05247216
- Locations
- 🇨🇳
Ningxia Hui Autonomous Region People's Hospital, Yinchuan, Ningxia, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: PlaceboDrug: 60mg Hemay005
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 306
- Registration Number
- NCT04839328
- Locations
- 🇨🇳
Peking University People's Hospital, Peking, Beijing, China
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT04837235
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 89
- Registration Number
- NCT04609397
- Locations
- 🇨🇳
Peking University Shougang Hospital, Beijing, Beijing, China
🇨🇳Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University, Guangzhou, Guangdong, China
A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 148
- Registration Number
- NCT04352595
- Locations
- 🇨🇳
Dermotology hospital, Chinese academy of medical science, Nanjing, Jiangsu, China
🇨🇳Ningbo second hospital, Ningbo, Zhejiang, China
Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: PlacebosDrug: 15mg Hemay005
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 216
- Registration Number
- NCT04102241
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Phase I Clinical Study of Hemay808
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT04100642
- Locations
- 🇨🇳
Dermotology hospital, Chinese academy of medical science, Nanjing, Jiangsu, China
Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT03977480
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Zhengzhou People's Hospital, Zhengzhou, Henan, China